en · de · es · fr · pt
melanotan-2-notes.peptides6579.com › Wiki › Melanotan-2 Structure And Receptor Pharmacology — Background and Details

Melanotan-2 Structure And Receptor Pharmacology — Background and Details

By Editorial Desk · published 2026-03-25 · last reviewed 2026-05-06 · Wiki

melanocortin receptor is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.

Last reviewed on 2026-05-06. Where a claim depends on a specific study, the study is described rather than over-claimed.

Melanotan-2 Structure and Receptor Pharmacology

Receptor studies place melanotan-2 among non-selective melanocortin agonists, binding MC1R, MC3R, MC4R and MC5R rather than a single subtype. Activation of MC1R on cutaneous melanocytes raises tyrosinase activity and shifts pigment synthesis toward eumelanin, which is darker and more photostable than pheomelanin. Central receptors, particularly MC4R, are associated with appetite suppression and with reported effects on sexual function. Because subtype selectivity is low, the same molecule engages pigment, metabolic and vascular pathways at once, and this breadth is a common explanation offered for the range of adverse events described in user reports.

No regulatory authority has approved melanotan-2 for human use, and several countries classify it as a prescription-only or controlled substance, which restricts lawful supply. Material sold online is generally labelled as a research chemical and is not required to meet pharmaceutical standards of identity or purity. Published human data consist mainly of small uncontrolled studies, case reports and adverse-event notifications, so the evidence base is descriptive rather than confirmatory. Whether repeated melanocyte stimulation alters long-term naevus behaviour remains an open question that no completed trial has resolved.

Handling, Storage, and Analytical Verification

Lyophilised melanotan-2 is supplied as a solid, which is more stable than a solution. The material is hygroscopic, so weighing is done quickly, in low humidity, with the container kept sealed. Reconstitution usually uses water for injection or bacteriostatic water, added down the wall of the vial to limit foaming. A reconstituted solution is held at 2 to 8 °C and kept away from light. Repeated freezing and thawing of the same vial is avoided because ice crystal formation and concentration effects degrade the peptide.

Reversed-phase high-performance liquid chromatography is the routine method for purity assessment. Peptides absorb near 214 nm because of the peptide bond, and a gradient of acetonitrile in water separates the intact peptide from deletion sequences, oxidised products, and earlier-eluting fragments at neutral pH. Electrospray ionisation mass spectrometry provides an orthogonal check: the measured mass must agree with the theoretical value. Amino acid analysis and peptide mapping confirm structure but are used less often. Reference standards remain scarce because the peptide is not described in any pharmacopoeia.

Melanotan-2 at a glance

PropertyValueNotes
Molecular formulaC50H69N15O9Free base; salt forms add to total mass
Molecular massAbout 1024 daltonsCalculated for the free base
Structural classCyclic heptapeptideContains D-phenylalanine and norleucine
Parent hormoneAlpha-melanocyte-stimulating hormoneEndogenous tridecapeptide of 13 residues
Receptor profileNon-selective melanocortin agonistInteracts with MC1R, MC3R, MC4R and MC5R

Chemical Background and Receptor Activity

Melanotan-2 is a synthetic cyclic heptapeptide designed as an analogue of alpha-melanocyte-stimulating hormone. Its sequence incorporates a lactam bridge that constrains the peptide into a ring, which increases resistance to enzymatic breakdown relative to the natural hormone. Researchers at the University of Arizona synthesised the compound in the late 1980s and early 1990s while studying pigmentation pathways. It has never received marketing approval from any national medicines regulator. In the scientific literature it is usually described as a laboratory research reagent rather than a therapeutic product.

The peptide acts as a non-selective agonist at melanocortin receptors, showing affinity for MC1R, MC3R, MC4R and MC5R. Activation of MC1R on melanocytes drives the conversion of tyrosine into melanin and shifts production toward the darker eumelanin form. MC4R signalling in the central nervous system is linked to appetite and energy balance, which helps explain why reduced food intake appeared in early human studies. Effects on MC4R and on vascular tone also account for the erectile responses recorded as unexpected findings in those same trials.

Melanotan-2 is frequently confused with afamelanotide, a linear analogue authorised in the European Union for erythropoietic protoporphyria. The two compounds differ in chain length, ring structure and receptor selectivity, so findings for one cannot be transferred directly to the other. Published controlled human data on melanotan-2 remain sparse, and much of what circulates online derives from small studies or unpublished reports. Questions about effect size, dose-response behaviour and long-term safety therefore remain unresolved.

Related pages on this site

Regulatory Status and Literature Discussion

Melanotan-2 has not received marketing authorisation from major regulatory agencies for any therapeutic indication. Several jurisdictions classify it as a prescription-only medicine or a controlled substance when supplied for human use. Because approved products do not exist, material sold online usually sits outside pharmaceutical supply chains and formal quality oversight. Regulators have issued public notices describing the compound as unapproved. Enforcement varies, and the legal position differs between countries, which complicates any single general statement about its status.

Scientific discussion of Melanotan-2 spans pharmacology, dermatology, and public-health literature. Laboratory studies examine its receptor binding and cellular effects, while clinical reports describe outcomes observed after unregulated use. These two bodies of work differ in rigour and intent. Peer-reviewed trials of the compound as a medicine are limited, so much of the available information comes from case reports and surveillance data. Authors frequently note the gap between experimental findings and real-world use.

Chemistry and Receptor Pharmacology

Melanotan II is a synthetic cyclic heptapeptide with the sequence Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-NH2, corresponding to a molecular formula of C50H69N15O9 and a monoisotopic mass near 1024 daltons. It was designed as a structural analogue of alpha-melanocyte-stimulating hormone, a peptide hormone produced by cleavage of proopiomelanocortin. A lactam bridge between the aspartate and lysine side chains closes the ring, and the C-terminal amide removes a free carboxyl group. Both modifications increase resistance to enzymatic degradation compared with the linear parent hormone. Four substitutions distinguish it from afamelanotide, the linear analogue studied under the name melanotan I.

Receptor-binding studies classify melanotan II as a non-selective melanocortin agonist. It interacts with MC1R, MC3R, MC4R and MC5R, with reported affinities in the low nanomolar range and no strong subtype preference. Activation of MC1R on dermal melanocytes shifts pigment synthesis toward eumelanin, the dark polymer deposited in melanosomes and transferred to keratinocytes. Because the same peptide engages MC4R in the hypothalamus, it also appears in animal work on food intake and erectile response, which is why it is discussed in both pigment and metabolic research. Which receptor populations dominate after systemic exposure in humans is not fully established.

Notes from published material

Genentech pioneered the use of recombinant human growth hormone for human therapy, which was approved by the FDA in 1985. Prior to its production by recombinant DNA technology, growth hormone used to treat deficiencies was extracted from the pituitary glands of cadavers. Attempts to create a wholly synthetic HGH failed. Limited supplies of HGH resulted in the restriction of HGH therapy to the treatment of idiopathic short stature. Very limited clinical studies of growth hormone derived from an Old World monkey, the rhesus macaque, were conducted by John C. Beck and colleagues in Montreal, in the late 1950s. The study published in 1957, which was conducted on "a 13-year-old male with well-documented hypopituitarism secondary to a crainiophyaryngioma," found that: "Human and monkey growth hormone resulted in a significant enhancement of nitrogen storage ... (and) there was a retention of potassium, phosphorus, calcium, and sodium. ... There was a gain in body weight during both periods. ... There was a significant increase in urinary excretion of aldosterone during both periods of administration of growth hormone. This was most marked with the human growth hormone. ... Impairment of the glucose tolerance curve was evident after 10 days of administration of the human growth hormone.

Cárdenas' capture in 2003 and extradition in 2007 weakened the cartel, but the resulting fragmentation and the independence of Los Zetas intensified violence in the context of the drug war, leaving a lasting legacy of conflict in Mexico in the decades that followed. Following the capture of Osiel Cárdenas Guillén in 2003 and his extradition in 2007, leadership fell to Jorge Eduardo Costilla Sánchez, a key figure in the Gulf Cartel, who led the criminal organization until 2012. Internal dynamics and rivalries, especially with Los Zetas, defined his era. The pursuit of Joaquín "El Chapo" Guzmán from 2001 to 2014 is a pivotal case in the context of the 21st-century global war on drugs, as it exemplifies the challenges of combating sophisticated transnational criminal organizations. Guzmán, as the leader of the Sinaloa Cartel, orchestrated one of the most powerful drug trafficking networks, responsible for smuggling vast quantities of narcotics into the United States and Europe, generating billions in illicit revenue. His 2001 escape from a high-security Mexican prison and subsequent evasion until his 2014 capture highlighted the systemic corruption, institutional weaknesses, and cross-border complexities that hinder effective counter-narcotics strategies. The operation to apprehend him, involving Mexican authorities and U.S.

=== Geneva lens measure === The Geneva Lens Measure is a device used to measure curved surfaces. It is most commonly used by opticians to measure lenses but can also be used by paleontologists to estimate the life size of dinosaur eggs from shell fragments. The instrument can be used to help estimate the size of fossil eggshells by measuring their curved surfaces. Since most eggs aren't perfectly round measurements from multiple parts of the egg with varying shell curvatures may be needed to get a full idea of the egg's size. Ideally an eggshell fragment being used to estimate the full size of an egg should be more than 3 cm long. Smaller eggshell fragments are better suited to other methods of study, like the Obrig radius dial gauge. The Geneva Lens measure gives units in diopters which must be converted to the radius in millimeters. Use of the Geneva Lens Measure to estimate the size of a fossil egg was first done by Sauer on fossil ostrich eggs.

Sources: en.wikipedia.org

Further detail

== Genetics == Gilbert syndrome is a phenotypic effect, mostly associated with increased blood bilirubin levels, but also sometimes characterized by mild jaundice due to increased unconjugated bilirubin, that arises from several different genotypic variants of the gene for the enzyme responsible for changing bilirubin to the conjugated form. Gilbert's syndrome is characterized by a 70–80% reduction in the glucuronidation activity of the enzyme UGT1A1. The UGT1A1 gene is located on human chromosome 2. More than 100 polymorphisms of the UGT1A1 gene are known, designated as UGT1A1*n (where n is the general chronological order of discovery), either of the gene itself or of its promoter region. UGT1A1 is associated with a TATA box promoter region; this region most commonly contains the genetic sequence A(TA)6TAA; this variant accounts for about 50% of alleles in many populations. However, several allelic polymorphic variants of this region occur, the most common of which results from adding another dinucleotide repeat TA to the promoter region, resulting in A(TA)7TAA, which is called UGT1A1*28; this common variant accounts for about 40% of alleles in some populations, but is seen less often, around 3% of alleles, in Southeast and East Asian people and Pacific Islanders. In most populations, Gilbert syndrome is most commonly associated with homozygous A(TA)7TAA alleles. In 94% of GS cases, two other glucuronosyltransferase enzymes, UGT1A6 (rendered 50% inactive) and UGT1A7 (rendered 83% ineffective), are also affected.

=== Hydrodynamic methods === To a first approximation, the basis for determination of molecular mass according to Mark–Houwink relations is the fact that the intrinsic viscosity of solutions (or suspensions) of macromolecules depends on volumetric proportion of the dispersed particles in a particular solvent. Specifically, the hydrodynamic size as related to molecular mass depends on a conversion factor, describing the shape of a particular molecule. This allows the apparent molecular mass to be described from a range of techniques sensitive to hydrodynamic effects, including DLS, SEC (also known as GPC when the eluent is an organic solvent), viscometry, and diffusion ordered nuclear magnetic resonance spectroscopy (DOSY). The apparent hydrodynamic size can then be used to approximate molecular mass using a series of macromolecule-specific standards. As this requires calibration, it's frequently described as a "relative" molecular mass determination method.

Freezer units are used in households and in industry and commerce. Food stored at or below −18 °C (0 °F) is safe indefinitely. Most household freezers maintain temperatures from −23 to −18 °C (−9 to 0 °F), although some freezer-only units can achieve −34 °C (−29 °F) and lower. Refrigerator freezers generally do not achieve lower than −23 °C (−9 °F), since the same coolant loop serves both compartments: Lowering the freezer compartment temperature excessively causes difficulties in maintaining above-freezing temperature in the refrigerator compartment. Domestic freezers can be included as a separate compartment in a refrigerator, or can be a separate appliance. Domestic freezers may be either upright, resembling a refrigerator, or chest freezers, wider than tall with the lid or door on top, sacrificing convenience for efficiency and partial immunity to power outages. Many modern upright freezers come with an ice dispenser built into their door. Some upscale models include thermostat displays and controls. Home freezers as separate compartments (larger than necessary just for ice cubes), or as separate units, were introduced in the United States in 1940. Frozen foods, previously a luxury item, became commonplace. In 1955 the domestic deep freezer, which was cold enough to allow the owners to freeze fresh food themselves rather than buying food already frozen with Clarence Birdseye's process, went on sale.

Sources: en.wikipedia.org

Background from the literature

=== Airfield === The Memphis airport occupies 3,900 acres (1,600 ha) and has four concrete runways. There is one east–west runway, 9/27, and three parallel north–south runways designated 18C/36C, 18L/36R, and 18R/36L. 18C/36C is the longest at 11,120 feet (3,390 m). The air traffic control tower was erected in 2011 and measures 336 feet (102 m). In 2022, the airport opened a new consolidated de-icing facility, which has a dedicated control tower and capacity for 12 wide-body planes.

oryzae with altered properties were generated by irradiation or by the CRISPR/CAS method. Similarly, mutants of A. sojae with altered properties were generated by a variant of the CRISPR/Cas method or chemical mutagenesis.

===== MeSH D08.811.913.555 – one-carbon group transferases (EC 2.1) ===== MeSH D08.811.913.555.150 – amidinotransferases MeSH D08.811.913.555.275 – carboxyl and carbamoyl transferases MeSH D08.811.913.555.275.200 – aspartate carbamoyltransferase MeSH D08.811.913.555.275.600 – ornithine carbamoyltransferase MeSH D08.811.913.555.400 – hydroxymethyl and formyl transferases MeSH D08.811.913.555.400.100 – aminomethyltransferase MeSH D08.811.913.555.400.300 – glutamate formimidoyltransferase MeSH D08.811.913.555.400.500 – glycine hydroxymethyltransferase MeSH D08.811.913.555.400.625 – phosphoribosylaminoimidazolecarboxamide formyltransferase MeSH D08.811.913.555.400.750 – phosphoribosylglycinamide formyltransferase MeSH D08.811.913.555.500 – methyltransferases MeSH D08.811.913.555.500.100 – acetylserotonin n-methyltransferase MeSH D08.811.913.555.500.175 – betaine-homocysteine S-methyltransferase MeSH D08.811.913.555.500.250 – catechol O-methyltransferase MeSH D08.811.913.555.500.350 – dna modification methylases MeSH D08.811.913.555.500.350.500 – dna (cytosine-5-)-methyltransferase MeSH D08.811.913.555.500.350.700 – site-specific dna-methyltransferase (adenine-specific) MeSH D08.811.913.555.500.350.850 – site-specific dna methyltransferase (cytosine-specific) MeSH D08.811.913.555.500.387 – glycine N-methyltransferase MeSH D08.811.913.555.500.425 – guanidinoacetate N-methyltransferase MeSH D08.811.913.555.500.500 – histamine N-methyltransferase MeSH D08.811.913.555.500.625 – homocysteine S-methyltransferase MeSH D08.811.913.555.500.645 – 5-methyltetrahydrofolate-homocysteine s-methyltransferase MeSH D08.811.913.555.500.650 – nicotinamide N-methyltransferase MeSH D08.811.913.555.500.700 – phenylethanolamine N-methyltransferase MeSH D08.811.913.555.500.710 – phosphatidyl-N-methylethanolamine N-methyltransferase MeSH D08.811.913.555.500.712 – phosphatidylethanolamine N-methyltransferase MeSH D08.811.913.555.500.800 – protein methyltransferases MeSH D08.811.913.555.500.800.400 – histone-lysine n-methyltransferase MeSH D08.811.913.555.500.800.650 – o-6-methylguanine-DNA methyltransferase MeSH D08.811.913.555.500.800.750 – protein-arginine n-methyltransferase MeSH D08.811.913.555.500.800.800 – protein o-methyltransferase MeSH D08.811.913.555.500.800.800.700 – protein d-aspartate-l-isoaspartate methyltransferase MeSH D08.811.913.555.500.862 – thymidylate synthase MeSH D08.811.913.555.500.925 – trna methyltransferases

Sources: en.wikipedia.org

Frequently asked questions

Is melanotan-2 approved for medical use?

No regulatory agency has authorised melanotan-2 as a medicine for any indication. It circulates mainly as a research chemical or through unregulated channels. As a result, identity, purity and content are not independently guaranteed.

How does melanotan-2 differ from melanotan-1?

Melanotan-1, also called afamelanotide, is a linear analogue with greater selectivity for MC1R and has received approval in some jurisdictions for a specific photosensitivity disorder. Melanotan-2 is cyclic, less selective, and reaches central receptors more readily. The two are often confused in online discussion despite different pharmacology and regulatory status.

What is the connection to alpha-MSH?

Alpha-MSH is an endogenous tridecapeptide derived from pro-opiomelanocortin. Melanotan-2 reproduces its core receptor-binding sequence inside a shortened, stabilised ring. The result is a molecule with a longer effective half-life and higher potency than the parent hormone.

Why are freeze-dried peptides kept cold?

Low temperature slows hydrolysis and oxidation, the two main routes by which the peptide backbone and side chains are modified. A lyophilised powder stored at −20 °C is more stable than one kept at room temperature, and once the material is dissolved the degradation rate rises, making refrigeration more important.

Network